Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) Director Lynne Chou O’keefe sold 10,045 shares in a trade that took place on Tuesday, June 21. The shares were sold at an average price of $4.35, for a total transaction of $43,695.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC’s website.
HIMS stock traded down $0.02 during Wednesday’s midday session, hitting $4.36. The company had a trading volume of 1,875,282 shares, compared to an average volume of 2,267,082 shares. The stock has a market capitalization of $894.12 million, a P/E ratio of -12.11 and a beta of 0.38. Hims & Hers Health, Inc. has a one-year low of $2.72 and a one-year high of $11.27. The stock’s 50-day simple moving average is $4.09 and its two-hundred-day simple moving average is $4.85.
Hims & Hers Health (NYSE:HIMS – Get Rating) last released its results on Monday, May 9. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analyst consensus estimates of ($0.09) by $0.01. The company posted revenue of $101.30 million for the quarter, compared to $90.99 million expected by analysts. Hims & Hers Health posted a negative return on equity of 22.41% and a negative net margin of 22.60%. The company’s quarterly revenue increased by 93.7% compared to the same quarter last year. During the same period last year, the company posted ($0.14) earnings per share. As a group, research analysts predict Hims & Hers Health, Inc. will post -0.35 earnings per share for the current fiscal year.
Several brokerages have published reports on HIMS. Deutsche Bank Aktiengesellschaft assumed coverage for Hims & Hers Health shares in a Thursday, March 10 research report. They issued a “hold” rating and a price target of $7.00 for the company. Guggenheim assumed Hims & Hers Health stock coverage in a Wednesday, April 13, research report. They set a “buy” rating and a price target of $10.00 for the company. Piper Sandler cut her price target on Hims & Hers Health shares from $8.00 to $6.00 and set an “overweight” rating for the company in a Thursday, May 26 research report. Finally, Citigroup cut its price target on Hims & Hers Health shares from $9.00 to $6.00 in a Tuesday, May 10 research report. Three investment analysts gave the stock a hold rating and three gave the company a buy rating. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.00.
Several hedge funds and other institutional investors have recently changed their holdings in HIMS. Redpoint Management LLC acquired a new position in Hims & Hers Health during the fourth quarter worth approximately $68,095,000. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health during the fourth quarter worth approximately $63,908,000. NewView HMS SPV Partners LLC acquired a new position in Hims & Hers Health during the first quarter worth approximately $51,506,000. Renaissance Technologies LLC increased its stake in Hims & Hers Health by 59.0% during the first quarter. Renaissance Technologies LLC now owns 1,682,600 shares of the company worth $8,968,000 after acquiring an additional 624,127 shares during the period. Finally, State Street Corp increased its stake in Hims & Hers Health by 6.8% during the first quarter. State Street Corp now owns 1,048,138 shares of the company worth $5,587,000 after acquiring an additional 66,501 shares during the period. Institutional investors and hedge funds own 57.22% of the company’s shares.
About health for him and her (Get an evaluation)
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The Company offers a range of health and wellness products and services available for purchase through its websites and mobile application directly by customers. It also provides recurrent prescription medication and ongoing care from health care providers; and over-the-counter drugs and devices, cosmetics, and supplements, primarily focused on wellness, sexual health and wellness, skin care, and hair care.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Hims & Hers Health right now?
Before you consider Hims & Hers Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Hims & Hers Health didn’t make the list.
While Hims & Hers Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here